top of page

The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity

Sep 6, 2024
1 min read

Pierre d'Epenoux describes how activating butyrophilin modulates γδ t-cells, science that has largely been explored in Marseille, and covers ImCheck's current clinical programs. Plus, what it is like being a biotech company in this area.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page